^
Association details:
Biomarker:CXCL10 overexpression
Cancer:Glioblastoma
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept

Excerpt:
Baseline cytokine and angiogenic factors associated with radiographic changes to aflibercept...Baseline levels of several markers predicted response to aflibercept. high expression of several monocyte-associated factors, including cutaneous T-cell-attracting chemokine (CTACK/CCL27), macrophage chemotactic protein-3 (MCP-3/CCL7), macrophage migratory inhibitory factor (MIF), and interferon-(IFN)-gamma-inducible protein 10 (IP-10/CXCL10) were all significantly associated with response: CTACK/CCL27: OR=15.49 (95% CI: 1.49–164.2), p=0.02; MCP3/CCL7: OR=9.3 (95% CI: 1.08–79.84), p=0.04; MIF: OR=2.59 (95% CI: 1.06–6.30), p=0.035; IP-10/CXCL10: OR=4.90 (95% CI: 1.19–20.09), p=0.028.
DOI:
10.1158/1078-0432.CCR-11-0271
Trial ID: